drugset / Trial / NCT00631488

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

NCT00631488

Phase 2 Completed 146 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.

Timeline

Start
2008-02
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0893 Small molecule 40 mg Oral
Subject Metformin Small molecule 1000 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral